INDIA MARKET LENS

Alkem Laboratories Limited (ALKEM): research summary

Price history, fundamentals, business-quality scores, DCF intrinsic value, shareholding, quarterly results and risk metrics for Alkem Laboratories Limited, explained in plain English.

  • Alkem Laboratories Limited is tracked in the Pharma & Healthcare sector of the NSE universe covered here.
  • ALKEM closed at ₹5,222.50 on 18 November 2026.
  • Over the past year the shares are down 8.6%, trading between ₹4,811.00 and ₹5,933.50.
  • Reported fundamentals show return on equity of 14.19%, a net margin of 13.23%, debt to equity of 14.72.
  • Our Pulse grade checklist scores it D (41/100) across momentum, growth, profitability and safety, using Pharma & Healthcare sector medians as the bar.
  • Annualised volatility over the past year is 22.5% with a maximum drawdown of -16.01% and a beta of 0.67 against NIFTY 50.
  • Recent coverage: Alkem Lab Q2 profit falls 14.4% to ₹667 cr; revenue rises to ₹4,552 cr
  • Recent coverage: Alkem Laboratories Q2 Results: Net Profit Falls 12% To Rs 675 Crore; Ropes In Gopal Kothari As CFO

Other Pharma & Healthcare companies: Abbott India, Acutaas Chemicals, Ajanta Pharmaceuticals, Anthem Biosciences, Apollo Hospitals Enterprise, Aster DM Quality Care, Aurobindo Pharma, Biocon

Last traded values from 18 Nov 2026. Market opens at 9:15 IST.

Alkem Laboratories Limited (ALKEM)

₹5,222.5

▲ 47.5 (+0.92%)

Price & volume

ALKEM price chart, 1Y range. 252 points from 2025-11-18 to 2026-11-18. Opens at 5,713, closes at 5,222.5, ranging between 4,947 and 5,890.5,0005,500Nov-25Jan-26Mar-26Apr-26Jun-26Aug-26Sep-26Nov-26volume

Hover for exact price & volume · green/red volume bars show up vs down days

Neutral momentum · 2/5
✓ Above 50-day avg✕ Above 200-day avgRSI 51 · healthyMACD ▼ fresh bearish crossBollinger %B 59ADX 18.3 · weak trend

1M

+3.42%

3M

-4.61%

6M

-4.49%

1Y

-8.59%

Where it sits in its 52-week range

29%
₹4,947₹5,890

Below 52-week high

11.3%

5.6% above the low

Momentum read

Neutral

2/5 checks passed

52-wk high

₹5,890

52-wk low

₹4,947

Market cap

₹62,443 Cr

P/E (trailing)

30.2

Dividend yield

—

ROE

14.19%

Profit margin

13.23%

Revenue growth

13.8%

Price / Book

4.2

Debt / Equity

14.72

EPS (TTM)

172.93

Book value

₹1243.21

Beta

0.67

Pulse grade: D, 41 out of 100

Momentum

C
  • ✓Trading above 50-day average
  • ✕Trading above 200-day average
  • ✓RSI in healthy 45-70 zone
  • ✕Positive 3-month return

Growth

F
  • ✕Revenue growth above Pharma & Healthcare median (20.8%)
  • ✓Revenue growing above 5%
  • ✕Quarterly profits trending up

Profitability

F
  • ✕Return on equity above Pharma & Healthcare median (14.56%)
  • ✓Return on equity above 12%
  • ✕Profit margin above Pharma & Healthcare median (13.82%)

Safety

A
  • ✓Debt below Pharma & Healthcare median (18.57)
  • ✓Debt not extreme for the sector
  • ✓Less volatile than the market (beta < 1.2)
  • ✕Pays a dividend

Quarterly revenue vs net profit

Revenue Net profit₹ crore, by quarter

Sep 2026: revenue ₹4,552 crore · net profit ₹675 crore · margin 14.8%

4,5520Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026

Business quality

Intrinsic value

Building the model…

Analyst coverage

Who owns this company

Events, dividends & splits

Market position

Pharma & Healthcare sector

PeerPrice ₹Day changeFrom 52-wk high
SUNPHARMA1,871.5+0.08%-6.48%
DRREDDY1,398.2+0.73%0.00%
CIPLA1,417+2.09%-7.46%
DIVISLAB11,049-0.91%-4.47%
APOLLOHOSP8,821+1.25%-2.73%
LUPIN1,971.9+1.12%-21.59%

ALKEM headlines

No ALKEM stories right now.

ALKEM filings & announcements

Reading the exchange…

ALKEM, historical timeline

The timeline will be ready shortly

The rest of the page is unaffected.

Risk & return, last 12 months

Volatility (ann.)

22.5%

Sharpe ratio

-0.57

Sortino ratio

-0.76

Max drawdown

-16.01%

Daily VaR (95%)

-1.88%

CAGR (1Y)

-8.62%

Return skew

-0.65

Sharpe/Sortino use a 7% risk-free rate. VaR-95 = the daily loss exceeded only 5% of days last year.

Risk profile over time

Quant tearsheet

Monthly returns, how deep the falls ran, and how tightly it tracks NIFTY.